Online inquiry

IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4270MR)

This product GTTS-WQ4270MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets LINGO1 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001301186.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84894
UniProt ID Q96FE5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4270MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4245MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ15247MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ15126MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ11040MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ8378MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ3793MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ12201MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ280MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW